Perioperative glucagon-like peptide-1 receptor agonist use is not associated with increased complications in obese patients undergoing total shoulder arthroplasty: a propensity-matched large database study
Authors:
- Argen OmurzakovAOArgen Omurzakov
- Arsen M. OmurzakovAOArsen M. Omurzakov
- Rajiv P. ReddyRRRajiv P. Reddy
- Mark MegerianMMMark Megerian
- Alexander E. WhiteAWAlexander E. White
- Miles MillerMMMiles Miller
- John M. ApostolakosJAJohn M. Apostolakos
- Samuel A. TaylorSTSamuel A. Taylor
- 25 July 2025
- journal article
- Published by Elsevier in Seminars in Arthroplasty: JSES
- Vol. 35 (4) , 604-611
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty SurgeonArthroplasty Today, 2024
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination TreatmentJAMA Network Open, 2024
- Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint ArthroplastyThe Journal of Arthroplasty, 2024
- Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trialeClinicalMedicine, 2024
- Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and ReadmissionsThe Journal of Arthroplasty, 2023
- Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?The Journal of Arthroplasty, 2023
- The incidence of shoulder arthroplasty: rise and future projections compared with hip and knee arthroplastyJournal of Shoulder and Elbow Surgery, 2020
- Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity2020
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsDiabetes & Metabolism, 2019
- National utilization of reverse total shoulder arthroplasty in the United StatesJournal of Shoulder and Elbow Surgery, 2015